Skip to main content
PLOS Neglected Tropical Diseases logoLink to PLOS Neglected Tropical Diseases
. 2021 Aug 27;15(8):e0009711. doi: 10.1371/journal.pntd.0009711

Control of snakebite envenoming: A mathematical modeling study

Shuaibu Ahijo Abdullahi 1,3, Abdulrazaq Garba Habib 2, Nafiu Hussaini 3,*
Editor: Adly MM Abd-Alla4
PMCID: PMC8428672  PMID: 34449762

Abstract

A mathematical model is designed to assess the impact of some interventional strategies for curtailing the burden of snakebite envenoming in a community. The model is fitted with real data set. Numerical simulations have shown that public health awareness of the susceptible individuals on snakebite preventive measures could reduce the number of envenoming and prevent deaths and disabilities in the population. The simulations further revealed that if at least fifty percent of snakebite envenoming patients receive early treatment with antivenom a substantial number of deaths will be averted. Furthermore, it is shown using optimal control that combining public health awareness and antivenom treatment averts the highest number of snakebite induced deaths and disability adjusted life years in the study area. To choose the best strategy amidst limited resources in the study area, cost effectiveness analysis in terms of incremental cost effectiveness ratio is performed. It has been established that the control efforts of combining public health awareness of the susceptible individuals and antivenom treatment for victims of snakebite envenoming is the most cost effective strategy. Approximately the sum of US$72,548 is needed to avert 117 deaths or 2,739 disability adjusted life years that are recorded within 21 months in the study area. Thus, the combination of these two control strategies is recommended.

Author summary

Snakebite envenoming (SBE) is currently one of the life-threatening neglected diseases especially in developing countries. The fight against this menace requires multidisciplinary approach. Owing to significant number of deaths and disabilities recorded per year in West African savanna region, we developed a new mathematical model for SBE in order to gain more insights into the dynamics and control of SBE. It is clear that communities in northeast Nigeria do not have adequate health information on self-protection against SBE and the antivenom is almost scarce and unaffordable. Thus, we evaluated the cost-effectiveness and potential impact of both public health awareness campaign and treatment for SBE as interventional strategies against snakebite. We discovered that public health awareness is crucial in averting SBE, deaths and disabilities. Also, if at least 50% of SBE victims received treatment within 24 hours of bite, a significant number of deaths and disabilities will be prevented. Furthermore, the study revealed that the combination of public health awareness and treatment decreases the burden of the disease in terms of deaths and disability adjusted life years at a lesser cost as compared with implementing one of these interventions separately. These results can be used as a guide for planning SBE control policy in northeast Nigeria and beyond.

Introduction

World Health Organization (WHO) defines snakebite envenoming (SBE) as a potentially life threatening disease that typically results from the injection of a mixture of different toxins (venom) following the bite of a venomous snake. SBE typically affects predominantly poor, rural communities in tropical and subtropical countries throughout the world and are significant threats to health and well-being of about 5.8 billion people around the world [1]. Harrison et al., in [2] reported that SBE mainly occurs in penurious settings, where most people engaged in agricultural or pastoral activities, such kind of occupations increase the risk of being bitten by snakes. After many years of neglect, in 2017 WHO reinstated SBE as a priority neglected tropical disease [3, 4]. In an effort to combat the threat caused by SBE in the affected regions worldwide, WHO sets out a plan to reduce snakebite deaths and disabilities by 50% before the year 2030 [1, 5].

One of the major challenges facing the control efforts on reducing SBE in some affected countries is inadequate reliable data. In some countries, the degree of underreporting is more than 70% particularly in rural areas where many snake bite victims use traditional medicine for treatment [6]. Despite the lack of data worldwide, about 4.5—5.4 million people are bitten by snakes every year, out of which 1.8—2.7 million develop envenoming with about 81,000—138,000 deaths. Furthermore, there are 400,000 cases of permanent disability due to this menace [69]. In sub-Saharan Africa, where the case of underreporting of data is high, over 250,000 people are reported as being bitten by snakes annually, with an estimated 7,000—20,000 deaths. The under-reporting claim is justified since in West Africa alone, there are 3,557—5,450 deaths that occur yearly. Also at one hospital in Nigeria, 6,687 snakebite cases were treated in just three years, [6, 10]. It has been reported that in sub-Saharan Africa, not less than 6,000 amputations occurred due to snakebite envenoming annually [11]. In Nigeria, Benue valley is the most affected region and has many underreported cases. Furthermore, it has an incidence of 497 per 100,000 population per year with 10—20% mortality [12, 13].

According to Warrell et al. in [14] three snake species carpet viper (Echis ocellatus), black-necked spitting cobra (Naja nigricollis), and puff adder (Bitis arietans) belonging to the Viperidae and Elapidae families are the most significant snakes related with envenoming in Nigeria. Carpet viper account for the majority of the envenoming in Nigeria.

According to WHO in [15], the best effective method of averting snakebite is through educating high-risk communities. Chappuis et al., in [16] recommended an enlightenment campaign to promote the use of protective measures against SBE in snake infested areas. Snake antivenom is considered to be the only treatment that can effectively cure or reverse the effect of snakebite envenoming, however, it may cause adverse reactions as reported in some studies [9, 1725].

A number of mathematical models have been developed to study the transmission dynamics and control of many neglected zoonotic diseases such as leishmaniasis, rabies, dengue, chagas disease, chikungunya (see for instance, [2634] and reference therein). Murray in [35], elucidated that snakebite envenoming shares some epidemiological features with zoonotic diseases. Accordingly, a mathematical model can serve as a tool to study the epidemiology of snakebite in order to gain more insights into its dynamics and control. Unlike other neglected tropical diseases such as dengue, rabies and malaria, to the best of our knowledge, only few research works have been done on mathematical modeling of SBE. Bravo et al, [36] proposed a model using law of mass action to estimate the incidence of snakebite. Also, Kim [37] developed a mathematical model based on the socio-demographic factors that influence mortality risk from SBE in India.

This study extends the above-mentioned models by designing a new mathematical model which incorporates public health awareness campaign as an intervention strategy. The model also includes early and late treatments as well as recovery with or without disabilities. Further, early adverse reaction because of antivenom therapy is considered [20, 24, 25]. It is noteworthy that this study will further assess different control strategies aimed at determining the most cost effective strategy for the control of SBE in the community.

Materials and methods

Model formulation

The human population at time t, denoted by NH(t), is divided into nine mutual exclusive compartments viz: unaware susceptible individuals, (SU(t)), aware susceptible individuals, (SE(t)), SBE individuals, (I(t)), individuals receiving early treatment with antivenom, (TE(t)), individuals receiving late treatment with antivenom, (TL(t)), individuals suffering from early adverse reaction (EAR) during early treatment, (VE(t)), individuals suffering from EAR during late treatment, (VL(t)), individuals who recovered with disabilities, (RD(t)), and individuals who recovered without disabilities, (RW(t)). Thus, the total human population is given by

N(t)=SU(t)+SE(t)+I(t)+TE(t)+TL(t)+VE(t)+VL(t)+RD(t)+RW(t). (1)

The total snake population is represented by (NS(t)). In this work, the aware susceptible individuals referred to those who have received appropriate public health awareness on how to protect themselves against snakebite. On the other hand, the unaware susceptible individuals are those who have not receive the public health awareness and therefore, are not using the protective measures against snakebite.

Model assumptions

The following are some of the major assumptions made in the construction of the model.

  1. Snakebite victim who received treatment with antivenom within 24 hours of bite (envenoming) is considered to be early treatment whereas antivenom administered after 24 hours of bite is regarded as late treatment [19, 38, 39].

  2. Early treatment is not associated with death and disability.

  3. Recovered individuals are allowed to move into aware susceptible class.

  4. It is assumed that the parameter θ ∈ [0, 1] measures the effectiveness of the public health awareness in reducing snakebite envenoming in the community. If θ = 0, the public health awareness campaign has no effect on the behavior of susceptible individuals, while if θ = 1 then the public health awareness campaign is 100% effective in improving the behavior of susceptible individuals towards taking protective measures against snakebite.

Model with constant controls

The schematic flow diagram depicted in Fig 1, illustrates the change of state by individuals in the population over time represented by solid lines. Further, it also demonstrates the interaction between humans and snakes in the population which is denoted by dot lines. Using the state variables and parameters of the model presented in Tables 1 and 2, respectively as well as the schematic flow diagram in Fig 1, a deterministic model describing the dynamics of SBE in a given population is established. The model is represented by the system of ordinary differential equations presented below. The complete description of the model is provided in the supplementary material S1 File.

dSUdt=ΛH-(λ+K1)SU,dSEdt=ϵSU+ϕ1RD+ϕ2RW-(Π1λ+K2)SE,dIdt=(Π1SE+SU)λ-K3I,dTEdt=τkI-K4TE,dTLdt=τΠ2I-K5TL,dVEdt=α1TE-K6VE,dVLdt=α2TL-K7VL,dRDdt=σ1ρ1TL+σ2ρ2VL-K8RD,dRWdt=γ1TE+γ2VE+σ1Π3TL+σ2Π4VL-K9RW,dNSdt=ΛSNS(1-NSKS)-μSNS,dDdt=δ1I+(TL+VL)δ2,λ(t)=βNSNH+NS, (2)

where,

K1=ϵ+μH,K2=μH,K3=τ+δ1+μH,K4=α1+γ1+μH,K5=α2+σ1+δ2+μH,K6=γ2+μH,K7=σ2+δ2+μH,K8=ϕ1+μH,K9=ϕ2+μH,Π1=1-θ,Π2=1-k,Π3=1-ρ1,Π4=1-ρ4,

subject to the initial conditions

SU(0)>0,SE(0)0,I(0)0,TE(0)0,TL(0)0,VE(0)0,VL(0)0,RD(0)0,RW(0)0,NS(0)0,D(0)0. (3)

Fig 1. Schematic diagram of the model.

Fig 1

The diagram describe the movement of individuals from one state to another.

Table 1. Description of state variables of the model.

Variables Description
SU(t) Unaware susceptible individuals.
SE(t) Aware susceptible individuals.
I(t) SBE individuals.
TE(t) Individuals receiving early treatment with antivenom.
TL(t) Individuals receiving late treatment with antivenom.
VE(t) Individuals suffering from early adverse reaction during early treatment.
VL(t) Individuals suffering from early adverse reaction during late treatment.
RD(t) Individuals who recovered with disabilities.
RW(t) Individuals who recovered without disabilities.
D(t) cumulative number of deaths due to snakebite.
NH(t) Total Population of humans.
NS(t) Population of snakes.

Table 2. Description of parameter of the model.

Parameter Description Units
ΛH Recruitment rate of unaware susceptible individuals Day −1
ΛS Population growth rate of Snakes Day −1
μH(μS) Natural mortality rates of humans (snakes) Day −1
β Effective snakebite envenomation rate Day −1
ϵ Rate of public health awareness campaign Day −1
θ Efficacy of public health awareness campaign. Nil
τ Rate at which SBE individuals receive treatment with antivenom Day −1
k Proportion of SBE individuals receiving early treatment with antivenom Nil
δi(i = 1, 2) SBE induced death rates in I, and TL and VL compartments respectively Day −1
αi(i = 1, 2) Rate at which individuals receiving treatment with antivenom suffer from EAR in TE and TL compartments respectively Day −1
γi(i = 1, 2) Recovery rate without disability of individuals in TE and VE compartments Day −1
σi(i = 1, 2) Recovery rate with disability of individuals in TL and VL compartments Day −1
ρi(i = 1, 2) Proportions of individuals who recovered with disabilities in TL and VL compartments respectively Nil
ϕi(i = 1, 2) Transition rates of individuals in RD and RW compartments to SE compartment Day −1
K S Carrying capacity of snake Nil

Model with time dependent controls

An optimal control problem is developed by incorporating the following time dependent control strategies into the constant control model given in Eq (2):

  1. u1(t) with 0 ≤ u1(t) ≤ 1 represents the control effort on educating the susceptible individuals on the risk associated with SBE. This control strategy promotes the use of protective measures such as hand gloves, boots, long sleeves wear etc.

  2. u2(t) with 0 ≤ u2(t) ≤ 1 is the control effort aimed at treating the SBE individuals with antivenom.

Two time dependent control variables are introduced to seek for the optimal result with least effort required to curtail the burden of SBE in the population at a minimum cost of implementation. Therefore, the optimal control model is given by

dSUdt=ΛH-(λ+ϵu1(t)+μH)SU,dSEdt=ϵu1(t)SU+ϕ1RD+ϕ2RW-((1-θ)λ+μH)SE,dIdt=((1-θ)SE+SU)λ-(τu2(t)+δ1+μH)I,dTEdt=τu2(t)kI-(α1+γ1+μH)TE,dTLdt=τu2(t)(1-k)I-(α2+σ1+(1-u2(t))δ2+μH)TL,dVEdt=α1TE-(γ2+μH)VE,dVLdt=α2TL-(σ2+(1-u2(t))δ2+μH)VL,dRDdt=σ1ρ1TL+σ2ρ2VL-(ϕ1+μH)RD,dRWdt=γ1TE+γ2VE+σ1Π3TL+σ2Π4VL-(ϕ2+μH)RW,dNSdt=ΛSNS(1-NSKS)-μSNS,dDdt=δ1I+(TL+VL)(1-u2(t))δ2,λ(t)=βNSNH+NS, (4)

with the initial conditions given by Eq (3).

To explore the optimal level of efforts that would be required to control snakebite envenoming in the study area, we constructed an objective functional J(u1, u2), whose goal is to minimize the number of snakebite envenoming individuals at time t, given by I(t), the cumulative number of snakebite induced death at time t, denoted by D(t) and the costs of applying the control efforts, u1 and u2, on public health education campaign for susceptible individuals and treatment of envenomed victims, respectively. In line with Rodrigues et al., [40], Agusto et al., [41], we used a quadratic cost functional with respect to the control variables u1 and u2 in order to guarantee convexity condition for optimality mentioned in Colaneri et al., [42]. Thus, the objective functional corresponding to the optimal control model in Eq (4) is given by

J(u1,u2)=0T(B1I(t)+B2D(t)+12i=12(Ciui2))dt, (5)

subject to the state system given by Eq (4). The goal is to minimize the number of SBE and death induced by same in the population at a minimal cost of implementing the control measures. In Eq (5), the quantities B1 and B2 are the weight constants corresponding to the population of SBE individuals and cumulative death induced by the disease respectively. While the quantities, C1 and C2 are the relative costs weight constants for the controls u1, and u2 respectively. We assume that the cost of each control is proportional to the square of its associated control function. The term C1u22 is the cost corresponding to the control effort on public health education of susceptibles on the risk associated with snakebite and the promotion of the use of protective measures. Similarly, C2u222 is the cost associated with the control effort on treating SBE patients. Note that the square of the controls indicates the non-linearity of cost function while the half-term minimizes the effect of applying the controls.

Our aim is to search for the controls functions (u1*,u2*) such that

J(u1*,u2*)=min{(u1,u2)|(u1,u2)Ψ}, (6)

where

Ψ = {(u1, u2)|ui(t) is Lebesgue measurable on [0, T], 0 ≤ ui(t) ≤ 1, i = 1, 2} is the control set of system Eq (4). The existence of the optimal controls and the derivation of the optimality system is reported in the supplementary S2 File.

Study area

This research focused on the northeast Nigeria which comprises six states that include Adamawa, Bauchi, Borno, Gombe, Taraba and Yobe as shown in Fig 2. According to National Bureau of Statistics (NBS) in [43] the projected total population of the six states in the northeast Nigeria is 26,263,866. Majority of people in this region engaged in agricultural activities such as farming, livestock rearing, and fishing. These activities placed them at high risk of snakebite. This region harbors some highly medically important snakes like carpet viper, black-necked spitting cobra, and puff adder. Snakebite Treatment and Research Hospital (STRH) is located in Kaltungo local government area in Gombe state which makes snakebite treatment accessible to people in the region. Kaltungo is one of the snakebite hot spots in Nigeria.

Fig 2. Map of Nigeria showing the study area.

Fig 2

The map portrays the states in the study area and the regional snakebite treatment center, Kaltungo. The map was extracted from public domain map: https://pubs.er.usgs.gov/publication/ofr7261 and modified using Golden Software Surfer 11.0.642.

Snakebite data collection

Data on snakebite is primarily collected from STRH in Gombe state, for the period of twenty one months from January, 2019 to September, 2020. These data include the number of SBE individuals, the number of individuals receiving early treatment with antivenom, the number individuals receiving late treatment with antivenom, the number of individuals suffering from EAR during late treatment,the number of individuals suffering from EAR during early treatment, the number of individuals recovered with disability, number of individuals recovered without disability, and the number of snakebite deaths as presented in supplementary S1 Table. The cumulative number of these seven different sets of data on snakebite cases will be used to fit the model as well as to performed some numerical simulations. Thus, the data used in this work are aggregated from all the six states that made up the study area. Note that all the seven sets of snakebite data collected are due to saw scaled viper (carpet viper).

Model fitting and parameters estimation

Real data collected from STRH is used to estimate the unknown parameters as well as to fit the model with the monthly reported data. The data is presented in supplementary S1 Table. The human and snake demographic parameters μH, ΛH and μS are parameterized as follows:

  • The total population of the study area is 26,263,866 [43].

  • Life expectancy of Nigeria as at 2018 is 54.332 years [44], μH=154.332, thus, μH = 5.04 × 10−6 per day.

  • Using the relation, ΛHμH=26,263,866, it follows that ΛH = 1324 per day.

  • The life expectancy of Saw-scaled viper is 12 years [45], so that μS=112 and hence μS = 2.283 × 10−4 per day.

Following Zu et al. [46], all other parameter values and the initial conditions of state variables in the model are estimated using the least square method and Markov Chain Monte Carlo (MCMC) technique. A set of results is estimated using the least square method with 100,000 number of iterations and the outcome is employed as initial guess for the MCMC method. To ensure the convergence of MCMC algorithm we used Gelman-Rubin diagnostic test implemented in MATLAB. We set the number of iteration to be 80000 with a burn-in of 40000 iterations. According to Gelman and Rubin [47], if chains have converged to the target posterior distribution, then Potential Scale Reduction Factor (PSRF) denoted by Rc should be sufficiently close to 1. The result in Table 3 shows that the Rc values are between 0.99 to 1.04 and thus all the chains have converged.

Table 3. The report of Gelman-Rubin diagnostics Test for MCMC.

Name of Parameter Values of Potential Scale Reduction Factor (RC)
β 1.0017
ϵ 0.9973
θ 1.0171
τ 1.0363
δ 1 0.9971
δ 2 0.9986
γ 1.0113
σ 0.9979
α 1 1.0086
α 2 1.0089
ρ 1 0.9985
ρ 2 1.0013
A S 1.0001
ϕ 1 0.9950
ϕ 2 1.0004
k 0.9991
SU(0) 1.0056
SE(0) 1.0260
NS(0) 1.0027
K S 1.0048

The estimated initial conditions and values of the parameters in the model are presented in Tables 4 and 5, respectively. The comparison between the estimated values by model and the real reported monthly data are depicted in Fig 3. The estimated outcomes of the model are in good agreement with the actual reported data. Therefore, the proposed model and the estimated parameter values can be used to predict the SBE incidence as well as understanding its dynamics in Nigeria and beyond.

Table 4. Estimated initial condition of state variables.

Variables Baseline 95% Confidence Interval Reference
SU(0) 2.1459 × 107 2.1097 × 107, 2.1820 × 107 Estimated
SE(0) 6.5132 × 103 (6.3876 × 103, 6.6388 × 103) Estimated
I(t) 99 - Reported data
TE(0) 76 - Reported data
TL(0) 7 - Reported data
VE(0) 8 - Reported data
VL(0) 0 - Reported data
RD(0) 4 - Reported data
RW(0) 93 - Reported data
NS(0) 1.2250 × 104 (1.2179 × 104, 1.2320 × 104) Estimated
DS(0) 2 - Reported data

Table 5. Estimated values of the model parameter.

Parameter Baseline 95% Confidence interval Units Reference
ΛH 1324 - Day −1 [43, 44]
ΛS 0.1925 (0.1924, 0.1926) Day −1 Estimated
μ H 5.04 × 10−6 - Day −1 [44]
μ S 2.283 × 10−4 - Day −1 [45]
β 0.0742 (0.0741, 0.0743) Day −1 Estimated
ϵ 0.0051 (0.0049, 0.0053) Day −1 Estimated
θ 1.7729 × 10−4 (0.524 × 10−4, 3.022 × 10−4) Nil Estimated
τ 0.9997 (0.9994, 1.0000) Day −1 Estimated
k 0.8073 (0.8070, 0.8076) Nil Estimated
δ 1 0.0025 (0.0023, 0.0028) Day −1 Estimated
δ 2 4.2564 × 10−4 (2.462 × 10−4, 6.05 × 10−4) Day −1 Estimated
α 1 0.1215 (0.1214, 0.1216) Day −1 Estimated
α 2 0.1708 (0.1706, 0.1709) Day −1 Estimated
γi(i = 1, 2) 0.9310 (0.9307, 0.9313) Day −1 Estimated
σi(i = 1, 2) 0.9924 (0.9898, 0.9950) Day −1 Estimated
ρ 1 0.1500 (0.1497, 0.1503) Nil Estimated
ρ 2 0.9985 (0.9982, 0.9987) Nil Estimated
ϕ 1 0.5233 (0.5231, 0.5234) Day −1 Estimated
ϕ 2 0.9416 (0.9384, 0.9448) Day −1 Estimated
K S 6.6604 × 104 (6.6457 × 104, 6.6752 × 104) Nil Estimated
Bi(i = 1, 2) 1 - Nil Assumed
C 1 0.28 - US$ Estimated
C 2 237 - US$ [4850]

Fig 3. Graphs showing the results of the model fitting with the reported data.

Fig 3

The model with constant controls is fitted with the reported cumulative number of (a) snakebite envenoming (b) early treatment (c) late treatment (d) EAR during early treatment (e) EAR during late treatment (f) recovered with disability (g) recovered without disability and (h) snakebite deaths. It can be seen that the model fitted well with the respective data sets collected from the snakebite treatment and research hospital, Kaltungo.

Estimation of cost of public health enlightenment campaign

We estimated per capita cost of public health awareness on the risk associated with SBE and its preventive measures in the study area. Broadcasting media and mobile technology are considered. From Tables 6 and 7, the total cost of enlightenment is US$7,332,887.23 and the total population of the study area is 26,263,866 [43]. Thus, per capita cost of public heath enlightenment is US$0.28.

Table 6. Estimation of cost of public health awareness on snakebite in 6 states of North East (NE) Nigeria using Broadcasting media.

Activity Resources needed Amount($) Reference
Jingle Production in 7 Languages. Audio 531.96 Reported
Jingle Production in 7 Languages. Video 2,127.82 Reported
Airing of jingle in Adamawa Radio stations 82,073.12 Reported
Television stations 20,974.24 Reported
Airing of jingle in Bauchi Radio stations 61,554.84 Reported
Television stations 20,974.24 Reported
Airing of jingle in Borno Radio stations 61,554.84 Reported
Television stations 20,974.24 Reported
Airing of jingle in Gombe Radio stations 61,554.84 Reported
Television stations 20,974.24 Reported
Airing of jingle in Taraba Radio stations 41,036.56 Reported
Television stations 41,948.48 Reported
Airing of jingle in Yobe Radio stations 41,036.56 Reported
Television stations 41,948.48 Reported
Total 444,562.66

Table 7. Estimation of cost of public health awareness on snakebite in six states of NE Nigeria using mobile phone.

Activity unit cost($) Population Frequency No of Months Amount($)
Bulk SMS 0.0051 14,069,290.38 8 12 6,888,324.57

Results and discussion

Numerical assessment of impact of public health awareness

Let us consider the following three different scenarios of applying the public health awareness using the model with constant controls:

  • CaseI: Low level of public health awareness campaign coverage and its efficacy (i.e. ϵ = θ = 10%).

  • CaseII: Moderate level of public health awareness campaign coverage and its efficacy (i.e. ϵ = θ = 50%).

  • CaseIII: High level of public health awareness campaign coverage and its efficacy (i.e. ϵ = θ = 90%).

The health benefits used for assessing the impact and effectiveness of the public health awareness campaign are the number of SBE, death and disability averted. The results in Table 8 and Fig 4 show that an increase in public health awareness increases the number of SBE averted cases as depicted in Fig 4A. In addition, the results further show that more number of death and disability are prevented when such intervention is increased in terms of coverage and efficacy (see Fig 4B and 4C). This outcome suggests that public health advocacy could serve as a strong non-pharmaceutical control measure of reducing the number of SBE, death and disability in the region.

Table 8. Simulations showing the impact and effectiveness of public health awareness over the period of 12 months.

Cases SBE averted Death averted Disability averted
Case I 1,120 10 57
Case II 10,515 111 609
Case III 20,075 223 1,200

Fig 4. Simulations showing the impact and effectiveness of public health awareness and early treatment.

Fig 4

The graphs clearly show the impact and effectiveness of public health awareness in averting number of (a) snakebite envenoming (b) snakebite induced death (c) disability. While (d) shows the impact of early treatment with antivenom on snakebite induced death. In Fig 4A, 4B and 4C the red, black, blue and green colors correspond to 0%, 10%, 50% and 90% public health awareness campaign coverage and its efficacy, respectively. In Fig 4D, the red, black, blue and green colors represent 0%, 10%, 50% and 90% of envenoming individuals receiving early treatment with antivenom.

Numerical assessment of impact of early treatment

Using the model with constant controls, numerical simulation is performed to appraise the potential impact of early treatment on the dynamics of SBE in terms of deaths averted for the period of one year, by considering the following scenario:

  • case I: 10% of SBE individuals receive early treatment (i.e. k = 10%).

  • case II: 50% of SBE individuals receive early treatment (i.e. k = 50%).

  • case III: 90% of SBE individuals receive early treatment (i.e. k = 90%).

The number of death averted corresponding to 10%, 50% and 90% of SBE victims that receive early treatment are 296, 918 and 1,146, respectively. This result indicates that an increase in proportion of individuals receiving early treatment increases the number of death averted over the period of time under study. In addition, the outcome depicted in Fig 4D illustrates that seeking for early treatment when snakebite occurs is very significant in reducing the number deaths due to SBE in the study area. It is observed that when more than 50% of SBE victims receive early treatment then scores of deaths will be prevented. This outcome suggests that even with adequate supply of effective and affordable antivenom as proposed by WHO in the road map to reduce snakebite mortality by 50% before the year 2030, if not administer at the right time, might not be able to reduce the death by half to meet WHO target. Thus, educating the risk population to seek for early treatment is also essential in achieving the set objectives.

Procedure for solving optimality system

In order to obtain solution for the optimality system which consists of state equations Eq (4), adjoint system in S2 File, the characterizations in S2 File and corresponding initial/final conditions, we apply the Runge-Kutta fourth order technique which is more accurate. It is a multiple-step method and also known as forward-backward sweep method (for detail description of this technique see [51]). The procedure starts with an initial guess on the control variable given initial conditions for the state variables, the solutions for the state equations will be approximated using the Runge-Kutta forward sweep technique. Given the state solutions from the preceding step and the final time conditions for adjoints, the solutions for adjoint equations will then be approximated using Runge-Kutta backward sweep method. The value of control variables is updated by taking the average of the preceding value and the new value arising from the control characterization. The procedure is repeated for forward numerical scheme and updating the controls until successive values of all states, adjoints, and controls converge.

Numerical simulation of the optimal control model

The numerical solutions of the consequential optimality system obtained in S2 File are carried out. The forward-backward sweep method is employed using the initials conditions and parameter values in Tables 4 and 5, respectively, with (σ1 = σ2 = 0.45, ϵ = θ = 0.65, k = 0.55). The algorithm starts with an initial guess of (u1, u2) = (0, 0) for the optimal controls and the state variables are then solved forward in time using Runge-Kutta method of the fourth order. Further, the state variables and initial control guess are used to solve the adjoint equations in S2 File backward in time with the given final condition in S2 File, using the backward fourth order Runge-Kutta method. The controls u1 and u2 are then updated and used to solve the state equations and then the adjoint system. This iterative process ends when the solutions converge. The simulations are carried-out over the period of 12 months. In order to demonstrate the effect of the implementation of the time dependent controls, the following strategies are considered:

  • Strategy A: public health awareness (i.e., u1) only,

  • Strategy B: treatment of SBE victims (i.e., u2) only,

  • Strategy C: combination of the strategies A and B (i.e., u1 and u2).

Fig 5 shows the impact of implementing the control strategies on the dynamics of SBE for the period of one year in the northeast Nigeria. It is observed that, as shown in Fig 5A, 5B and 5C, at the beginning of the first three months, the impact of the control strategies implemented either independently or simultaneously are insignificant. After this period a significant reduction in the number of snakebite induced deaths is noticed. Further, implementation of strategy C averts more deaths followed by strategy A. It is noteworthy that whenever any of these control strategies is implemented, it has to be maintained over the planning horizon in order to control the number of deaths. On the other hand, in the absence of control measures, the rate of death is significantly high. Fig 5D, presents the effect of implementing control strategy A on snakebite envenoming.

Fig 5. Simulation results of the optimal control model.

Fig 5

The simulation results of the optimal control model showing the effectiveness of (a) strategy A in averting the number of snakebite induced deaths as against without strategy, (b) strategy B in averting the number of snakebite induced deaths as against without strategy, (c) strategy C in averting the number of snakebite induced deaths as against without strategy, (d) strategy A in averting number of snakebite envenoming as against without strategy. In the graphs the solid line denotes without strategy while dotted line indicates with control strategy.

It is shown in S1 Fig, that the optimal solution is attained when the control effort on public health enlightenment is firmly observed at maximum level from the onset and should be maintained for approximately the period of 11.16 months before relaxing the control effort to the barest minimum. In case of the control effort on the treatment of SBE patients, the optimal solution is attained when the control effort is rapidly increased to reach the maximum level at 0.12 months and is maintained for the period of 11.88 months before reducing it to zero. Consequently, to reduce the burden of SBE in terms of deaths avertion within the planning horizon of one year, these control efforts must be maintained at a maximum level.

Cost-effectiveness analysis

In this section, we compared the costs and benefits of the different control strategies employed to avert snakebite induced death with particular reference to northeast Nigeria. In recent times, cost effectiveness analysis has become an important tool to many researchers especially in the field of mathematical epidemiology see for instance [5255]. For effective allocation of resources to control snakebite cases, public health decision makers need to know the impact and cost-effectiveness of snakebite prevention and treatment programmes. In order to choose the right intervention policy, a cost-effectiveness ratio (CER) in terms of incremental cost-effectiveness ratio (ICER) is calculated. Furthermore, the effectiveness of an intervention is measured in terms of Quality Adjusted Life Years (QALYs), deaths prevented or infections averted. In this study, snakebite induced death and Disability Adjusted Life Year (DALY) averted are employed as health benefit of the control interventions. In line with Hove-Musekwa et al., [52] and Adamu et al., [55], a linear cost function with respect to the control variables u1 and u2 of the cost effectiveness analysis for the control strategies is used. The total discounted cost function for control strategy i, is given by;

Costi=0T(C1u1ϵSU+C2u2(kTE+(1-k)TL)τ+α1VE+α2VL)e-rtdt, (7)

where r = 5% is a discount rate [52] and i = A, B, C. Following Weinstein [56], the formula for computing ICER for two competing strategies I and J is given by

ICERI,J=CostI-CostJDeathAvertedI-DeathAvertedJ (8)

Using Eq (8) the ICER for strategies A, B and C are computed as follows:

ICERA=6.4615×1065.8570×103=1.1032×103,
ICERB,A=(3.0030-6.4615)×106(4.3161-5.8570)×106=2.2445×103,
ICERC,B=(7.3100-3.0030)×106(7.2254-4.3161)×106=1.4804×103.

The results of the ICER for strategies A, B and C are presented in Table 9. Comparing strategy A and strategy B, it is obvious that the ICERA is less than ICERB,A. This shows that strategy B is less effective than strategy A, meaning that strategy B is dominated. Therefore, strategy B is removed from the list. Accordingly, the ICER of strategies A and C are evaluated using analogous technique and the result is presented in Table 10.

Table 9. ICER of control strategies in the order of death averted.

Strategy Death averted Cost of strategy($) ICER/($)
Strategy A 5,857 6,461,500 1,103.2
Strategy B 4,316.1 3,003,000 2,244.5
Strategy C 7,225.4 7,310,000 1,480.4

Table 10. Comparison between ICER of strategies A and C.

Strategy Deaths averted Cost of strategy($) ICER/($)
Strategy A 5,857 6,461,500 1,103.2
Strategy C 7,225.4 7,310,000 620.07

The result in Table 10 shows that strategy A is dominated by strategy C because ICERC,A is less than ICERA. This suggests that strategy A is more costly and less effective than strategy C. Therefore, implementation of control efforts on public health awareness and treatment simultaneously is the most cost-effective strategy. This strategy is capable of averting more number of deaths at a lesser cost of implementation. Using the criteria for choosing cost effectiveness threshold based on per capita Gross Domestic Product (GDP) established in [57], strategy C is highly cost effective in the region, because its ICER is less than threefold per capita GDP of Nigeria. According to [58], the estimated per capita GDP of Nigeria as at 2019 is $2,229.9. Following this criteria, strategy A is just cost effective since its ICER per death averted is less than twofold per capita GDP. Thus, strategy C is recommended because of its capability of averting highest number deaths at a lesser cost. The criteria for selecting cost effectiveness threshold of strategy based on per capita GDP of a region or country for developing countries is presented as follows. A strategy is considered to be:

  1. highly cost effective if the ICER is less than one times per capita GDP;

  2. cost effective if the ICER is between one times per capita GDP and less than threefold per capita GDP;

  3. not cost effective if the ICER is greater than threefold per capita GDP.

Following Habib, et al., [49] and Hamza et al., [50], 23.41 discounted DALYs approximation is equivalent to one early mortality due to snakebite. Therefore, the deaths averted by each strategy shown in Table 9, column 2, were converted to DALYs by taking the product of the total number of deaths averted by each strategy and 23.41 DALYs and the results are shown in Table 11 column 2. Consequently, we computed the ICER in terms of DALY averted as health benefit yielding a cost/DALY averted of $95.88 for strategy B which is similar to the earlier findings in [49] and [50] (see Table 11). However, the cost/DALY averted for strategy B is still higher than that of strategy A, thus, the former is eliminated from the list. The result in Table 12 shows that strategy C averts more DALY at a lesser cost than strategy A. It is noteworthy that when DALY is used as health benefit in the computation of ICER, the outcome shows that all the strategies are highly cost effective using per capita GDP based criteria and strategy C is the best to be recommended for policy implementation.

Table 11. ICER of control strategies in the order of DALY averted.

Strategy DALY averted Cost of strategy($) ICER($)
Strategy A 137,112.37 6,461,500.00 47.13
Strategy B 101,039.90 3,003,000.00 95.88
Strategy C 169,146.61 7,310,000.00 63.24

Table 12. Comparison between ICER of strategies A and C in terms of DALY.

Strategy DALY averted Cost of strategy($) ICER($)
Strategy A 137,112.37 6,461,500.00 47.13
Strategy C 169,146.61 7,310,000.00 26.49

It has been shown that 117 deaths occurred within 21 months in the study area because of snake bites (see, S1 Table). However, these number of deaths could have been prevented by using strategy C as an intervention, which has the minimum implementation cost of US$72,548 in comparison to the sum of US$129,074 and US$262,607 that would be required for the execution of strategies A and B, respectively. Each of these strategies would greatly reduce the number of snakebite induced-deaths in the region. Using SBE averted cases as health benefit, the implementation of strategy A only needs about US$6,461,500 to avert 751,800 cases over a 12-month period (i.e., US$8.59 per averted case). The sum of US$34,429 is required to implement strategy A in order to avert 4008 SBE cases recorded over 21-month period (see, S1 Table). Therefore, this would serve as a guide to both the government and non-governmental organizations in the northeast Nigeria towards reducing the burden of SBE and its related deaths by 50% before the year 2030.

Effect of early adverse reaction (EAR) on the cost of control strategy

Suppose that the rates at which individuals on antivenom therapy suffer from EAR are set to zero (i.e. α1 = α2 = 0). This means that nobody who received an antivenom treatment will develop EAR. Further, if strategy B or C is implemented, the results presented in Tables 13 and 14 unveiled a substantial reduction in cost/death and cost/DALY averted in comparison to the ones obtained in Tables 9 and 11, respectively. Therefore, reducing the incidence of antivenom reactions by increasing its safety will curtail the cost of managing SBE burden in the study area.

Table 13. ICER of control strategies in the order of death averted.

Strategy Death averted Cost of strategy($) ICER($)
Strategy B 4,316.20 3,229,600.00 2,100.55
Strategy C 7,227.90 7,391,100.00 1,429.23

Table 14. ICER of control strategies in the order of DALY averted.

Strategy DALY averted Cost of strategy($) ICER($)
Strategy B 101,042.24 3,229,600.00 89.73
Strategy C 169,205.14 7,391,100.00 61.05

Conclusion

A new mathematical model for studying the dynamics of snakebite envenoming (SBE) in a given population is proposed. In the model, treatment and public health enlightenment campaign against SBE are considered as control strategies. Furthermore, the model considered some epidemiological characteristic of snakebite as one of the neglected tropical diseases. The model is fitted using real reported data on snakebite collected from snakebite treatment and research hospital (STRH) Kaltungo, Nigeria. The main findings of the study are as follows:

  1. The assessment of public health awareness of susceptible population revealed that the control strategies are significant in controlling the disease in terms of averting the number of SBE cases, deaths and disabilities in the community.

  2. If at least 50% of SBE patients received early treatment more than 900 cases of death will be averted in the study area.

  3. The implementation of the control strategies either separately or in combination will help in reducing the number of death in the community. However, the combination of the two control strategies averts more than 7,227 deaths and 169,205 DALYs in the population. Given the synergistic reduction in the cost per DALY averted with the two interventions implemented simultaneously compared to when only antivenom is used, the annual amount of US$51–66 million needed to halve the burden in Sub-Saharan Africa (SSA) using antivenom solely [48] will also lessen substantially when antivenom therapy is implemented together with other control measures.

  4. The cost effectiveness analysis showed that combination of the two strategies is the most cost effective way of handling SBE in the study area.

  5. The sum of US$262,607, US$129,074 and US$72,548 are, respectively, required for each to avert 117 deaths or 2,739 DALYs. Also the sum of US$34,429 is needed in order to avert 4008 SBE cases by using public health enlightenment campaign as an intervention.

  6. Early adverse reaction has significant impact on the cost per death and cost per DALY averted when an antivenom is used for treatment separately or in combination with public health enlightenment campaign against SBE.

To the best of the authors’ knowledge, this is the first time a study mixing epidemiological modeling with optimal control is applied to snakebite. The model can also be used to assess snakebite envenoming in other settings or countries of high incidence.

Limitation of the study

This study has the following limitations. Our model could be extended to include some other important epidemiological and demographic features like the spatial and temporal dimensions of human-snakes interaction and also the impact of seasonality on the dynamics of envenoming. Furthermore, the data we collected did not capture unreported cases in the study area and the total population of saw scale viper was estimated not counted. The assumption that only saw scale viper is considered could be relaxed to include multiple species of snakes provided the relevant data could be obtained. Also more control variables could be incorporated into the model to take care of other possible control measures like use of snake repellent, etc.

Supporting information

S1 File. Model description.

(PDF)

S2 File. Existence of an optimal control.

(PDF)

S1 Table. Monthly reported data on SBE collected from treatment and research Hospital Kaltungo, Gombe State, Nigeria (from January, 2019—September, 2020.

(PDF)

S1 Fig. Graphs showing the control profile of optimal control strategies.

(TIF)

Acknowledgments

We would like to acknowledge, with thanks, the support of Dr. Mukaila Abdullahi for designing the map of the study area. Also, special thanks to Dahiru Ibrahim Sajoh of Modibbo Adama University of Technology, Nigeria for his help in the model simulations.

Data Availability

All relevant data are within the manuscript and its Supporting information files.

Funding Statement

SAA would like to acknowledge, with thanks, the support of global Snakebite Initiative (GSI)/Hamish Ogston Foundation (HOS). While AGH wishes to appreciate the support of African Snakebite Research project Group (ASRG) and Scientific Research Partnership for Next Generation Snakebite Therapies (SRPNTS) supported by National Institutes of Health Research (UK) and Department for International Development (DFID), respectively. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.World Health Organization. Snakebite envenoming: a strategy for prevention and control. Geneva: License: CC BY-NC-SA 3.0 IGO.2019.
  • 2.Harrison RA, Hargreaves A, Wagstaff SC, Faragher B,Lalloo DG. Snake envenoming: a disease of poverty. 2009. PLoS Negl. Trop. Dis. 3, e569. doi: 10.1371/journal.pntd.0000569 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Lancet. The Snake-bite envenoming: a priority neglected tropical disease. Lancet. 2017; 390(10089). [DOI] [PubMed] [Google Scholar]
  • 4.Chippaux JP. Snakebite envenomation turns again into a neglected tropical disease J Venom Anim Toxins Incl Trop Dis. 2017; 23:38. doi: 10.1186/s40409-017-0127-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.World Health Organization. Resolution WHA71.5. Addressing the burden of snakebite envenoming. Geneva.2018.
  • 6.World Health Organization. Prevalence of snakebite envenoming. Accessed on 20th February, 2020 from; https://www.who.int/snakebites/epidemiology/en/
  • 7.Chippaux JP. Snake-bites: appraisal of the global situation. Bull World Health Organ. 1998; 76(5):515–24. Epub 1998/12/30. [PMC free article] [PubMed] [Google Scholar]
  • 8.Kasturiratne A, Wickremasinghe AR, de Silva N, Gunawardena NK, Pathmeswaran A, Premaratna R, et al. The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med. 2008; 5(11):e218. Epub 2008/11/07. doi: 10.1371/journal.pmed.0050218 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Gutierrez JM, Calvete JJ, Habib AG, Harrison RA, Williams DJ, Warrell DA. Snakebite envenoming. Nat Rev Dis Primers. 2017; 3:17063. doi: 10.1038/nrdp.2017.63 [DOI] [PubMed] [Google Scholar]
  • 10.Habib AG, Kuznik A, Hamza M, Abdullahi MI, Chedi BA, Chippaux J-P, et al. Snakebite is Under Appreciated: Appraisal of Burden from West Africa. PLOS Neglected Tropical Diseases. 2015; 9(9), e0004088–. doi: 10.1371/journal.pntd.0004088 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Chippaux JP. Estimate of the burden of snakebites in sub-Saharan Africa: a meta-analytic approach. Toxicon. 2011; 57, 586–599. doi: 10.1016/j.toxicon.2010.12.022 [DOI] [PubMed] [Google Scholar]
  • 12.Habib AG, Gebi UI, Onyemelukwe GC. Snake bite in Nigeria. Afr J Med Med Sci. 2001; 30(3):171–8. [PubMed] [Google Scholar]
  • 13.Pugh RNH, Theakston RDG. Incidence and mortality of snake bite in savannah Nigeria. Lancet. 1980; 2, 1181–1183. doi: 10.1016/S0140-6736(80)92608-2 [DOI] [PubMed] [Google Scholar]
  • 14.Warrell DA, Davidson NMD, Greenwood BM. Poisoning by bites of the saw-scaled or carpet viper (Echis carinatus) in Nigeria. Q J Med. 1977; 46:33–62. [PubMed] [Google Scholar]
  • 15.World Health Organization. Regional Office for Africa. Guidelines for the prevention and clinical management of snakebite in Africa. 2010. WHO http://apps.who.int/medicinedocs/documents/s17810en/s17810en.pdf
  • 16.Chappuis F, Sharma SK, Jha N, Loutan L, Bovier PA. Protection against snakebites by sleeping under a bednet in southeastern Nepal. Am. J. Trop. Med. Hyg. 2007; 77, 197–199. [PubMed] [Google Scholar]
  • 17.Warrell DA. Snake bite. Lancet (London, England). 2010; 375(9708):77–88. doi: 10.1016/S0140-6736(09)61754-2 [DOI] [PubMed] [Google Scholar]
  • 18.Williams D, Gutierrez JM, Harrison R, Warrell DA, White J, Winkel KD, et al. The Global Snake Bite Initiative: an antidote for snake bite. Lancet (London, England). 2010; 375(9708):89–91. doi: 10.1016/S0140-6736(09)61159-4 [DOI] [PubMed] [Google Scholar]
  • 19.Habib AG. Public health aspects of snakebite care in West Africa: perspectives from Nigeria. J Venom Anim Toxins Incl Trop Dis. 2013; 19, 27. doi: 10.1186/1678-9199-19-27 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Morais VM, Massaldi H. Snake antivenoms: adverse reactions and production technology. J Venom Anim Toxins incl Trop Dis. 2009; 15(1):3.doi: 10.1590/S1678-91992009000100002 [DOI] [Google Scholar]
  • 21.Warrell DA. Clinical toxicology of snakebite in Africa and the Middle East/Arabian peninsula, Asia. In: Meier J, White J eds. Handbook of Clinical Toxicology of Animal Venoms and Poisons. Florida, CRC Press. 1995; 433–594. [Google Scholar]
  • 22.Malasit P, Warrell DA, Chanthavanich P, Viravan C, Mongkolsapaya J, Singhthong B, Supich C. Prediction, prevention, and mechanism of early (anaphylactic) antivenom reactions in victims of snake bites. British Medical Journal. 1986; 292 (6512), 17–20. doi: 10.1136/bmj.292.6512.17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Maduwage K. Snakebite coagulopathy: controversies in understanding and management. Sri Lanka Journal of Medicine. 2017; 26(2):38–54. doi: 10.4038/sljm.v26i2.39 [DOI] [Google Scholar]
  • 24.Habib AG. Effect of pre-medication on early adverse reactions following antivenom use in snakebite: a systematic review and meta-analysis. Drug Saf. 2011Oct1; 34(10):869–80. doi: 10.2165/11592050-000000000-00000 [DOI] [PubMed] [Google Scholar]
  • 25.de Silva HA, Pathmeswaran A, Ranasinha CD, Jayamanne S, snakebite Samarakoon, Hittharage A., Kalupahana R., Ratnatilaka GA, Uluwatthage W, Aronson JK, Armitage JM, Lalloo DG, de Silva HJ. Low-dose adrenaline, promethazine, and hydrocortisone in the prevention of acute adverse reactions to antivenom following snakebite: a randomised, double-blind, placebo-controlled trial. PLoS Med. 2011May; 8(5):e1000435. doi: 10.1371/journal.pmed.1000435 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Hussaini N, Okuneye K, Gumel AB. Mathematical analysis of a model for zoonotic visceral leishmaniasis Infectious Disease Modelling. 2017; 2, 455–474 doi: 10.1016/j.idm.2017.12.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Okuneye K, Gumel AB. Analysis of a temperature and rainfall-dependent model for malaria transmission dynamics, Mathematical Biosciences. 2016; 000, 1–21. [DOI] [PubMed] [Google Scholar]
  • 28.Velascohernandez. A Model of Chagas Disease Invoving Transmision by vectors and Blood Transfusion. Theoritical Population Biology. 1994; 46(1):1–31. doi: 10.1006/tpbi.1994.1017 [DOI] [PubMed] [Google Scholar]
  • 29.Shigui R. Modeling the transmission dynamics and control of rabies in China. Mathematical Biosciences. 2017; 286, 65–93. doi: 10.1016/j.mbs.2017.02.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Zhang J, Jin Z, Sun GQ, Zhou T, Ruan S. Analysis of Rabies in China: Transmission Dynamics and Control. PLoS ONE. 2011;6(7): e20891. doi: 10.1371/journal.pone.0020891 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Yakob L, Clements ACA. A Mathematical Model of Chikungunya Dynamics and Control: The Major Epidemic on Reunion Island. PLoS ONE. 2013; 8(3):e57448. doi: 10.1371/journal.pone.0057448 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Sabiu SM, Hussaini N. Modelling the Dynamics of Chikungunya in human and mosquito populations. Bayero Journal of Pure and Applied Sciences (Special Conference Edition): 2017; 10(1): 634–641. doi: 10.4314/bajopas.v10i1.118S [DOI] [Google Scholar]
  • 33.Sabiu SM, Hussaini N, Zhao S, Daihai H. Dynamical Analysis of Chikungunya and Dengue Coinfection Model. DISCRETE AND CONTINUOUS DYNAMICAL SYSTEMS SERIES B. May2020; 25(5).1907–1933. doi: 10.3934/dcdsb.2020009 [DOI] [Google Scholar]
  • 34.Adamu L, Hussaini N. An Epidemic Model of Zoonotic Visceral Leishmaniasis with Time Delay. J. Nig. Soc. Phys. Sci. 2019; 1 (2019) 20–29. doi: 10.46481/jnsps.2019.5 [DOI] [Google Scholar]
  • 35.Murray KA, Martin G, I T. Focus on snake ecology to fight snakebite. Lancet. 2020;395: e14. doi: 10.1016/S0140-6736(19)32510-3 [DOI] [PubMed] [Google Scholar]
  • 36.Bravo-Vega CA, Cordovez JM, Renjifo-Ibanez C, Santos-Vega M, Sasa M. Estimating snakebite incidence from mathematical models: A test in Costa Rica. PLoS Negl Trop Dis. 2019; 13(12): e0007914. doi: 10.1371/journal.pntd.0007914 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Kim S. Introduction of a Mathematical Model to Characterize Relative Risk of Snakebite Envenoming, a Neglected Tropical Disease. [Thesis]: the degree of Honors Baccalaureate of Science in Kinesiology: Oregon State University, University Honors College. 2020.
  • 38.Syed MA, Mohib AA, Jyotsna M, Adarash C, Jyotishka P. Emergency treatment of a snake bite: Pearls from literature, J Emerg Trauma Shock. 2008; 1(2): 97–105. doi: 10.4103/0974-2700.43190 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Reidi HA, Theakston RDG. The Management of Snake bite. Bulletin of the World Health Organization. 1983; 61 (6): 885–895. [PMC free article] [PubMed] [Google Scholar]
  • 40.Rodrigues P, Silva CJ, Torres DFM. Cost-Effectiveness Analysis of Optimal Control Measures for Tuberculosis. Bulletin of Mathematical Biology. 2014; 76(10), 2627–2645. doi: 10.1007/s11538-014-0028-6 [DOI] [PubMed] [Google Scholar]
  • 41.Agusto FB, ELmojtaba IM, Schallig Henk DFH. Optimal control and cost-effective analysis of malaria/visceral leishmaniasis co-infection. PLOS ONE. 2017; 12(2), e0171102–. doi: 10.1371/journal.pone.0171102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Colaneri P, Middleton RH, Chen Z, Caporale D, Blanchini F. Convexity of the cost functional in an optimal control problem for a class of positive switched systems. Automatica. 2014; 50(4), 1227–1234. doi: 10.1016/j.automatica.2014.02.025 [DOI] [Google Scholar]
  • 43.National Bureau of Statistics/Nigerianstat.gov.ng/#pop, accessed November, 2020.
  • 44.https: World Bank Data. https://data.worldbank.org/indicator/SP.DYN.LEOO.MA,IN?locations=NG, accessed November, 2020.
  • 45.World Life Expectancy. ANIMALLIFEEXPECTANCY. https://www.worldlifeexpectancy.com/reptile-life-expectancy-saw-scaled-viper accessed 14th October 2020.
  • 46.Zu J, Li ML, Li ZF, Shen MW, Xiao YN, Ji FP. Transmission patterns of COVID-19 in the mainland of China and the efficacy of different control strategies: a data- and model-driven study. Infectious Diseases of Poverty. 2020; 9(1). doi: 10.1186/s40249-020-00709-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Gelman A, Rubin DB. Inference from Iterative Simulation Using Multiple Sequences. Statistical Science. 1992; 7:457–511. doi: 10.1214/ss/1177011136 [DOI] [Google Scholar]
  • 48.Habib AG, Musa BM, Iliyasu G, Hamza M, Kuznik A, Chippaux J-P. Challenges and prospects of snake antivenom supply in sub-Saharan Africa. PLoS Negl Trop Dis. 2020; 14(8):e0008374. doi: 10.1371/journal.pntd.0008374 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Habib AG, Lamorde M, Dalhat MM, Habib ZG, Kuznik A. Cost-effectiveness of Antivenoms for Snakebite Envenoming in Nigeria. PLoS Negl Trop Dis. 2015; 9(1): e3381. doi: 10.1371/journal.pntd.0003381 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Hamza M, Idris MA, Maiyaki MB, Lamorde M, Chippaux JP, Warrell DA, et al. Cost-Effectiveness of Antivenoms for Snakebite Envenoming in 16 Countries in West Africa. PLoS Negl Trop Dis. 2016; 10(3): e0004568. doi: 10.1371/journal.pntd.0004568 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Lenhart SM, Workman JT. Optimal Control Applied to Biological Models, CRC Press. 2007 [Google Scholar]
  • 52.Hove-Musekwa DS, Nyabadza F, Mambili-Mamboundou H, Chiyaka C, Mukandavire Z. Cost-Effectiveness Analysis of Hospitalization and Home-Based Care Strategies for People Living withHIV/AIDS: The Case of Zimbabwe. International Scholarly Research Notices. 2014; (2014).1–13. doi: 10.1155/2014/836439 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Smith JA, Sharma M, Levin C, Baeten JM, van Rooyen H, Celum C, Barnabas RV. Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis. The Lancet HIV. 2015; 2(4), e159e168. doi: 10.1016/S2352-3018(15)00016-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Asamoah JKK, Owusu MA, Jin Z, Oduro FT, Abidemi A, Gyasi EO. Global stability and cost-effectiveness analysis of COVID-19 considering the impact of the environment:using data from Ghana. Chaos, Solitons & Fractals. 2020. doi: 10.1016/j.chaos.2020.110103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Ishaku A, Gazali AM, Abdullahi SA, Hussaini N. Analysis and optimal control of an HIV model based on CD4 count. Journal of Mathematical Biology. 2020. doi: 10.1007/s00285-020-01508-8 [DOI] [PubMed] [Google Scholar]
  • 56.Weinstein M. From cost-effectiveness ratios to resource allocation: Where to draw the line? In: Sloan F. (Ed.), Valuing Health Care: Costs, Benefits, and Effectiveness of Pharmaceuticals and Other Medical Technologies, Cambridge University Press, New York. 1996; 77–97. [Google Scholar]
  • 57.Sachs JD. Macroeconomics and health: investing in health for economic development. Technical Report. Geneva: World Health Organisation. 2001.
  • 58.World Bank Data. Gross Domestic Product per Capita (Current international $) for Nigeria. https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=NG Accessed 27th December, 2020.
PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0009711.r001

Decision Letter 0

Adly MM Abd-Alla, Abdallah M Samy

23 Mar 2021

Dear Dr. Hussaini,

Thank you very much for submitting your manuscript "Control of snakebite envenoming: a mathematical modeling study" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments.

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Adly M.M. Abd-Alla, Prof asso.

Associate Editor

PLOS Neglected Tropical Diseases

Abdallah Samy

Deputy Editor

PLOS Neglected Tropical Diseases

***********************

Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: The objectives of the study are clearly articulated. The study design is generally appropriate, with some concerns indicated below. The population selected for this model analysis is adequate, and the statistical mathematical analysis seems appropriate as well. As this is a mathematical modeling study, there are no ethical concerns.

The authors should consider the following aspects in their methodology:

-The terms ‘Enlighted’ or ‘enlightening’ are not the most appropriate to describe the effect of public education campaigns in snakebite envenoming. The authors may consider using alternative terms such as ‘awareness’ or ‘instructed’. The point here is to underscore the effect of these campaigns in the general awareness or information at the community level. In my view ‘enlightening’ has a different meaning. This is presented to the authors for their consideration.

-Model formulation: When defining the human population, nine categories are proposed and added in the formula. However, the same person may be included in two or more different categories, for example somebody that was ‘enlightened’ and at the same time receive early antivenom treatment. Thus, addition of these categories may provide a mistaken number depending on whether one person may be in two or more categories.

-Method: Control efforts for educating susceptible individuals: the parameter here is whether an individual or groups of individuals were ‘enlightened’ by providing information. But the doubt remains as how to know whether the persons that received the information indeed learned the concepts transmitted and is now ‘enlightened’. It seems that some sort of evaluation of the knowledge acquired should be introduced in the analysis as to provide a follow up of the effective assimilation of the information provided, i.e., a post-hoc evaluation.

Fig 2: To help the readers locate the region of study in the map of Nigeria, it is suggested that this map includes also the whole map of Nigeria, highlighting the study are.

In the description of the ‘enlightening’ campaigns, only two modalities are considered, i.e., broadcasting material and mobile technology. However, owing to the variety of cultural settings in Nigeria and similar countries it seems that there should be more options for ‘enlightening’ campaigns, such as presential activities in communities, organization of focus groups in schools and other modalities that would adapt to the local contexts. This will increase the cost of these campaigns but will ensure a better communication landscape. The authors may want to include these issues in the discussion of the design and the analysis pf the model proposed.

The model of Bravo et al. considers the density of the snake population. This variable is not used in the currently proposed model for Nigeria. The authors may want to comment on this, especially since there might be regions in their analysis with a different density of snake populations.

Reviewer #2: -Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

The study main objective is to apply epidemiological models to then perform optimal control to reduce burden of snakebite mortality and incidence taking into account the cost of performing prevention strategies and improving antivenom delivery.

-Is the study design appropriate to address the stated objectives?

Authors used an adequate epidemiological model, but the box diagram must be improved. It looks tight and is difficult to read. Then, authors adjusted the model by using parameters from literature and by fitting other parameters with MCMC, which is an adequate methodology. They MUST explain why they assumed the saw scaled viper as the only venomous snakes in their total venomous snakes population. Finally, their optimal control strategy is clear, but they MUST explain deeply the objective function, and why they summed weighted incidence and mortality with their strategies (These variables doesn't have the same dimensions, so the weight variables B1, B2 and Ci must be explained deeplier).

-Is the population clearly described and appropriate for the hypothesis being tested?

They used as a case study northeast Nigeria, a place that has a high burden of snakebite, so the study area and population is appropiate.

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

The sample size is not explicit, because it is not clear if they worked with dissagregated data from the six states of northeast Nigeria, or if they aggergated data. This fact must be explained deeplier.

-Were correct statistical analysis used to support conclusions?

MCMC confidence intervals aseems adequate, but authors do not talk about the convergence of the chains of the algorithm. Maybe using a gelman-rubin diagnostic. Also, the optimal control strategy doesn't have the evidence of the convergence.

-Are there concerns about ethical or regulatory requirements being met?

No.

--------------------

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: The analysis presentes match well with the analysis plan. The results are clearly and completely presented. The figures and tables could be improved along the lines indicated below.

Effects of public health enlightenment campaigns: In addition to the objective criteria of reduction in SBE as an outcome of the enlightening campaigns, it would be interesting to consider evaluation of improvement in knowledge on how to prevent snakebites through instruments that follow up the knowledge acquired by people that attended or benefited from the campaigns.

The variables ‘enlightening’ and early treatment of snakebites are considered as separate parameters in the analysis. However, there seems to be a clear link between them, since it is likely that people that benefit from the enlightening campaigns would also be people that would procure an early attention to snakebites, assuming that they will not look for traditional treatments that delay the access to health facilities.

Table 14: The meaning of the heads of each column should be indicated in a foot note, i.e., the meaning of I, CI, TE, CTE, etc.

Reviewer #2: -Does the analysis presented match the analysis plan?

Results are great, graphics could be improved in aesthetics, but their contests match the analysis plan. Just as said before, authors must go deeplier into the convergence of MCMC chains and their optimal control strategy.

-Are the results clearly and completely presented?

The paper has a strongly mathematical-biased language, which must be changed to be more comprehensible for the multi-disciplinar audience of PLOS NTDS. Even so, results and conclusions fits totally the requirements of originality, importance and rigurous methodology required by the journal.

-Are the figures (Tables, Images) of sufficient quality for clarity?

Images have a high-quality methodology and importance behind them, but they are not clearly explained and their aesthetics can be improved. The box-diagram of the epidemiological model seems of bad quality, and it looks tight. The figures 3 to 5 must be explained beeter in the image caption: What do you want to point with these plots? Do the model fit well de data? What is the impact of the level of education? What means these strategies A and B in terms of the results shown in Figure 5, what strategy is better? Are necessary the control profiles, or they can go to supplementary materials? These profiles must be explained deeplier in the caption of the figure.

--------------------

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: The conclusions are generally supported by the data and analyses done, although there are some issues indicated above that need to be considered.

The authors may consider to include, at the end of their manuscript, a section discussing the limitations of the analysis.

The method proposed and described has evident implications from the public health perspective, as it provides interesting tools to model issues related to snakebite envenoming and ways to reduce their impact, including cost-effectiveness analysis.

Reviewer #2: -Are the conclusions supported by the data presented?

Yes, but they could be more direct: ii) What is that substancial number of deaths reduced by that strategy? iii) How many dalys and deaths will be reduced by combining strategies?

-Are the limitations of analysis clearly described?

No. They don't state the limitations of only using population dynamics of one venomous snake, or the possible effect of seasonality and temporal dynamics of the envenoming, or the limitations of the assumptions behind the proposed model, or what happen with underreporting. A limitations section must be added.

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Not so much. This work has a GREAT potential, but that potential is not stated directly. Maybe at the end of conclusions you should add that is the first time that a study mixing epidemiological modeling with optimal control is applied to snakebite, and how can this framework be extrapolated to other countries, and how to use it with fragmented or incomplete datasets.

--------------------

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: (No Response)

Reviewer #2: 1. They MUST explain why they assumed the saw scaled viper as the only venomous snakes in their total venomous snakes population. Finally, their optimal control strategy is clear

2. They MUST explain deeply the objective function, and why they summed weighted incidence and mortality with their strategies (These variables doesn't have the same dimensions, so the weight variables B1, B2 and Ci must be explained deeplier).

3. The sample size is not explicit, because it is not clear if they worked with dissagregated data from the six states of northeast Nigeria, or if they aggregated data. This fact must be explained deeplier.

4. Convergence of MCMC chains and optimization must be stated clearly.

5.The paper has a strongly mathematical-biased language, which must be changed to be more comprehensible for the multi-disciplinar audience of PLOS NTDS.

6. Improve figures: The box-diagram of the epidemiological model seems of bad quality, and it looks tight. The figures 3 to 5 must be explained beeter in the image caption: What do you want to point with these plots? Do the model fit well de data? What is the impact of the level of education? What means these strategies A and B in terms of the results shown in Figure 5, what strategy is better? Are necessary the control profiles, or they can go to supplementary materials? These profiles must be explained deeplier in the caption of the figure.

7. Authors must add a limitation section on discussion: Why only use population dynamics of one venomous snake species, what about seasonality and temporal dynamics of the envenoming, which are the limitations of the assumptions behind the proposed model, what happen with underreporting.

8.This work has a GREAT potential, but that potential is not stated directly. Maybe at the end of conclusions you should add that is the first time that a study mixing epidemiological modeling with optimal control is applied to snakebite, and how can this framework be extrapolated to other countries, and how to use it with fragmented or incomplete datasets.

--------------------

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: Mathematical modeling is not my main area of expertise and, therefore, there might be aspects of the development of the model that could be improved and escape my analysis. However, this study is valuable in the sense that a mathematical model approach to assess snakebite envenoming in countries of high incidence, like Nigeria, are badly needed and, in that sense, this contribution is welcomed. The model described could be extrapolated to other settigns and countries. I have a number of concerns with this study which were explained above.

Reviewer #2: The study uses strong mathematical tools to fit epidemiological models to public health data, and then they use these models to perform optimal control based on 2 strategies of prevention and treatment availability. This is a novel approach in snakebite, where these strategies has been proposed but its effect has not been quantified. The significance in snakebite is high, because based on these studies finally the proposed strategies can be evaluated and included into public health scope.

The paper have weaknesses: The language is directed to a mathematic public, which is not the only public of plos NTDS. This must be changed. Also, there are some data that is missing: Which is the spatial scale that they used? An aggregated for northeast Nigeria? Or the states of this areas? Did the MCMC chains converged? How they assure that they find the optimum? Also, the figures can be improved to fullfil the aesthetics required in a high-impact journal as PLOS NTDS. Even so these weaknesses exist, if the authors fix them the study will be suitable to be published in the journal, because authors did a great job.

--------------------

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Carlos Andres Bravo-Vega

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0009711.r003

Decision Letter 1

Adly MM Abd-Alla, Abdallah M Samy

26 Jun 2021

Dear Dr. Hussaini,

Thank you very much for submitting your manuscript "Control of snakebite envenoming: a mathematical modeling study" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.

Please prepare and submit your revised manuscript within 30 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Adly M.M. Abd-Alla, Prof asso.

Associate Editor

PLOS Neglected Tropical Diseases

Abdallah Samy

Deputy Editor

PLOS Neglected Tropical Diseases

***********************

Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: In this revised version the authors have adequately addressed the comments to the methodology.

Reviewer #2: The article improved a lot! Great job. There are still minor issues that should be addressed easily.

The table of the parameters in the methodology does not have units. Please add them similar to the table of the estimated parameters in results.

Why does u1 and u2 are squared in the objective function if both variables are between 0 and 1? It is not totally clear why do you want to have a cost function non linear.

Why does the factor of u1 and u1 in the objective function have no weight? (Or weight =1?) Please explain this.

The block diagramm quality and map of study area is low, it pixelates when zoom is applied. Please upload a higher resolution version.

--------------------

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: (No Response)

Reviewer #2: Why is the cost function of Cost-effectiveness analysis different than the one presented in the methodology (Objective function?) This function does not have the squares that are present in the method cost function. Please explain deeplier this new function and its differences with cost function of the methodology.

Please explain deeplier how did you computed the DALYS.

--------------------

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: The conclusions are convincing and supported by the results.

Reviewer #2: Please state more limitations of the model, as which limitations must be taken into account for its appliaction in other countries? In terms of the assumptions, the species, the available data needed to calibrate the model and perform optimal control, and how can be these limitations overcomed.

--------------------

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: I do not have further suggestions for modifications

Reviewer #2: Please increase the resolution of the Figure 1 and 2.

Plase upload the code for the study to any data repository recommended by the journal.

--------------------

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: (No Response)

Reviewer #2: The study, as I've said before, has a great potential because it is the first time that optimal control and epidemiological modeling has been applied to snakebite.

--------------------

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Carlos Bravo-Vega

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

References

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article's retracted status in the References list and also include a citation and full reference for the retraction notice.

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0009711.r005

Decision Letter 2

Adly MM Abd-Alla, Abdallah M Samy

5 Aug 2021

Dear Dr. Hussaini,

We are pleased to inform you that your manuscript 'Control of snakebite envenoming: a mathematical modeling study' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Adly M.M. Abd-Alla, Prof asso.

Associate Editor

PLOS Neglected Tropical Diseases

Abdallah Samy

Deputy Editor

PLOS Neglected Tropical Diseases

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0009711.r006

Acceptance letter

Adly MM Abd-Alla, Abdallah M Samy

20 Aug 2021

Dear Dr. Hussaini,

We are delighted to inform you that your manuscript, "Control of snakebite envenoming: a mathematical modeling study," has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Model description.

    (PDF)

    S2 File. Existence of an optimal control.

    (PDF)

    S1 Table. Monthly reported data on SBE collected from treatment and research Hospital Kaltungo, Gombe State, Nigeria (from January, 2019—September, 2020.

    (PDF)

    S1 Fig. Graphs showing the control profile of optimal control strategies.

    (TIF)

    Attachment

    Submitted filename: Response_Reviwers_08_03_21.docx

    Attachment

    Submitted filename: Response to Reviewers_Comments.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting information files.


    Articles from PLoS Neglected Tropical Diseases are provided here courtesy of PLOS

    RESOURCES